22nd Century Group Files Renewal for VLN® Reduced Nicotine Tobacco Products
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 06 2026
0mins
Should l Buy XXII?
Source: Globenewswire
- Innovative Product Renewal: 22nd Century Group has filed a Modified Risk Tobacco Product renewal application for its VLN® reduced nicotine tobacco products, with the FDA authorizing claims of “95% less nicotine,” which will further solidify the company's leadership in tobacco harm reduction.
- Significant Market Impact: A 2024 marketplace study showed that smokers using VLN® tobacco reduced their daily consumption by 40% over 12 weeks, indicating the product's effectiveness in reducing smoking and increasing quit attempts, potentially leading to improved public health outcomes.
- Brand Expansion Strategy: An increasing number of cigarette brands are launching VLN® products, offering alternatives with 95% less nicotine, which helps smokers reduce their nicotine intake while maintaining their habits, thereby enhancing market competitiveness.
- Proactive Regulatory Support: The company anticipates full FDA support for its renewal application, especially as VLN® products meet the FDA's proposed low nicotine guidelines, further reinforcing its market position.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy XXII?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on XXII
About XXII
22nd Century Group, Inc. is a tobacco products company that enables cigarette smokers to take control of their consumption of nicotine, the addictive drug in cigarettes. The Company manufactures and distributes combustible tobacco products containing minimally or non-addictive levels of nicotine. Additionally, the Company provides turnkey contract manufacturing of cigarettes and filtered cigars for other established tobacco brands. The Company's product, VLN cigarette has 95% less nicotine than the traditional cigarette. The Company operates through a single segment named Tobacco. It is engaged in contract manufacturing organization (CMO) customer contracts that consist of obligations to manufacture the customers' branded filtered cigars and cigarettes. It is also engaged in the sale of its proprietary low nicotine content cigarettes, sold under the brand name VLN, or research cigarettes sold under the brand name SPECTRUM.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Oversold Stocks in Consumer Staples Sector Present Buying Opportunities
- Buying Opportunity: Stocks in the consumer staples sector with an RSI below 30 are considered oversold, presenting opportunities to invest in undervalued companies, especially during market fluctuations.
- Instacart Performance: Instacart (NASDAQ:CART) shares have fallen approximately 18% over the past month, with an RSI of 29.3 indicating potential for a short-term rebound, as analysts maintain a Buy rating.
- Price Target Adjustment: Stifel analyst Mark Kelley lowered the price target for Instacart from $49 to $46, reflecting a cautious market outlook on the company's future performance while providing investors with a chance to buy at a lower price.
- Market Dynamics Analysis: Other oversold stocks in the consumer sector, such as Coffee Holding Co. and 22nd Century Group, also show investment potential, allowing investors to assess short-term trading opportunities through RSI indicators.
See More
22nd Century Group (XXII) Announces 1-for-15 Reverse Stock Split to Comply with Nasdaq Standards
- Reverse Stock Split Announcement: 22nd Century Group announced a 1-for-15 reverse stock split effective January 26, 2026, aimed at reducing the outstanding shares from 7,652,661 to approximately 510,177 to comply with Nasdaq's continued listing standards.
- Market Reaction: Following the announcement, shares of 22nd Century Group fell 7.24% in pre-market trading to $0.75, indicating negative market sentiment towards the split and potential impacts on investor confidence.
- New CUSIP Number: The new CUSIP number for the company's stock post-split will be 90137F608, ensuring investors can accurately identify and trade the new shares.
- Compliance Pressure: The reverse stock split reflects the company's urgent response to Nasdaq compliance pressures, highlighting its strategic adjustments to maintain its listing status.
See More
22nd Century Group Completes Restructuring, Launches VLN® Reduced-Nicotine Products
- Successful Restructuring: In 2025, 22nd Century Group completed a multi-year restructuring, strengthening its financial foundation and reinforcing its leadership in tobacco harm reduction, demonstrating the company's execution capabilities and long-term value creation in a complex regulatory environment.
- Product Innovation: The launch of the VLN® reduced-nicotine cigarette, authorized by the FDA and containing approximately 95% less nicotine, enables smokers to significantly reduce nicotine dependence in a short period, aligning with health and wellness consumer trends.
- Market Expansion: VLN® product distribution has expanded to nearly 2,000 retail locations across over 20 states, with growing consumer awareness driving demand for reduced-nicotine alternatives, further propelling the company's commercial growth.
- Financial Strength: By the end of 2025, the company achieved a debt-free balance sheet with improved liquidity, providing flexibility for future strategic execution and positioning the company towards sustainable profitability.
See More
22nd Century Group CEO to Present at Needham Growth Conference
- Management Presentation: 22nd Century Group's CEO Larry Firestone and CFO Dan Otto will present at the Needham Growth Conference on January 16, 2026, showcasing the company's innovations and leadership in the tobacco industry.
- Investor Engagement: The management team will be available for virtual one-on-one meetings, allowing investors to book appointments through their Needham representatives or the company's investor relations email, enhancing communication and transparency with stakeholders.
- Product Innovation Context: The company's VLN® cigarettes contain 95% less nicotine, designed to help smokers control their nicotine consumption, reflecting the unique positioning and market demand within the tobacco industry.
- Patent Technology Advantage: With an extensive patent portfolio, the company ensures exclusive access to low-nicotine combustible cigarettes in the U.S. and critical international markets, further solidifying its competitive edge and industry leadership.
See More
22nd Century Group Files Renewal for VLN® Reduced Nicotine Tobacco Products
- Innovative Product Renewal: 22nd Century Group has filed a Modified Risk Tobacco Product renewal application for its VLN® reduced nicotine tobacco products, with the FDA authorizing claims of “95% less nicotine,” which will further solidify the company's leadership in tobacco harm reduction.
- Significant Market Impact: A 2024 marketplace study showed that smokers using VLN® tobacco reduced their daily consumption by 40% over 12 weeks, indicating the product's effectiveness in reducing smoking and increasing quit attempts, potentially leading to improved public health outcomes.
- Brand Expansion Strategy: An increasing number of cigarette brands are launching VLN® products, offering alternatives with 95% less nicotine, which helps smokers reduce their nicotine intake while maintaining their habits, thereby enhancing market competitiveness.
- Proactive Regulatory Support: The company anticipates full FDA support for its renewal application, especially as VLN® products meet the FDA's proposed low nicotine guidelines, further reinforcing its market position.
See More
88th Emerging Growth Conference Scheduled for December 10-11, 2025
- Conference Schedule: The 88th Emerging Growth Conference is set for December 10-11, 2025, featuring a diverse range of growth companies showcasing their innovative products and services, aimed at attracting investor interest.
- Presenting Companies: Keynote speakers from firms such as OSR Holdings (NASDAQ: OSRH) and SBC Medical Group (NASDAQ: SBC) will present, likely increasing investor engagement and interest in these companies.
- Interactive Opportunities: Attendees can submit questions to presenting companies, fostering communication between investors and firms, which enhances the effectiveness of investment decisions.
- Media Impact: The conference serves as a platform for companies to showcase their offerings, effectively attracting potential investors and enhancing market visibility, which could lead to potential stock price increases.
See More
Oversold Stocks in Consumer Staples Sector Present Buying Opportunities
- Buying Opportunity: Stocks in the consumer staples sector with an RSI below 30 are considered oversold, presenting opportunities to invest in undervalued companies, especially during market fluctuations.
- Instacart Performance: Instacart (NASDAQ:CART) shares have fallen approximately 18% over the past month, with an RSI of 29.3 indicating potential for a short-term rebound, as analysts maintain a Buy rating.
- Price Target Adjustment: Stifel analyst Mark Kelley lowered the price target for Instacart from $49 to $46, reflecting a cautious market outlook on the company's future performance while providing investors with a chance to buy at a lower price.
- Market Dynamics Analysis: Other oversold stocks in the consumer sector, such as Coffee Holding Co. and 22nd Century Group, also show investment potential, allowing investors to assess short-term trading opportunities through RSI indicators.
See More
22nd Century Group (XXII) Announces 1-for-15 Reverse Stock Split to Comply with Nasdaq Standards
- Reverse Stock Split Announcement: 22nd Century Group announced a 1-for-15 reverse stock split effective January 26, 2026, aimed at reducing the outstanding shares from 7,652,661 to approximately 510,177 to comply with Nasdaq's continued listing standards.
- Market Reaction: Following the announcement, shares of 22nd Century Group fell 7.24% in pre-market trading to $0.75, indicating negative market sentiment towards the split and potential impacts on investor confidence.
- New CUSIP Number: The new CUSIP number for the company's stock post-split will be 90137F608, ensuring investors can accurately identify and trade the new shares.
- Compliance Pressure: The reverse stock split reflects the company's urgent response to Nasdaq compliance pressures, highlighting its strategic adjustments to maintain its listing status.
See More
22nd Century Group Completes Restructuring, Launches VLN® Reduced-Nicotine Products
- Successful Restructuring: In 2025, 22nd Century Group completed a multi-year restructuring, strengthening its financial foundation and reinforcing its leadership in tobacco harm reduction, demonstrating the company's execution capabilities and long-term value creation in a complex regulatory environment.
- Product Innovation: The launch of the VLN® reduced-nicotine cigarette, authorized by the FDA and containing approximately 95% less nicotine, enables smokers to significantly reduce nicotine dependence in a short period, aligning with health and wellness consumer trends.
- Market Expansion: VLN® product distribution has expanded to nearly 2,000 retail locations across over 20 states, with growing consumer awareness driving demand for reduced-nicotine alternatives, further propelling the company's commercial growth.
- Financial Strength: By the end of 2025, the company achieved a debt-free balance sheet with improved liquidity, providing flexibility for future strategic execution and positioning the company towards sustainable profitability.
See More
22nd Century Group CEO to Present at Needham Growth Conference
- Management Presentation: 22nd Century Group's CEO Larry Firestone and CFO Dan Otto will present at the Needham Growth Conference on January 16, 2026, showcasing the company's innovations and leadership in the tobacco industry.
- Investor Engagement: The management team will be available for virtual one-on-one meetings, allowing investors to book appointments through their Needham representatives or the company's investor relations email, enhancing communication and transparency with stakeholders.
- Product Innovation Context: The company's VLN® cigarettes contain 95% less nicotine, designed to help smokers control their nicotine consumption, reflecting the unique positioning and market demand within the tobacco industry.
- Patent Technology Advantage: With an extensive patent portfolio, the company ensures exclusive access to low-nicotine combustible cigarettes in the U.S. and critical international markets, further solidifying its competitive edge and industry leadership.
See More
22nd Century Group Files Renewal for VLN® Reduced Nicotine Tobacco Products
- Innovative Product Renewal: 22nd Century Group has filed a Modified Risk Tobacco Product renewal application for its VLN® reduced nicotine tobacco products, with the FDA authorizing claims of “95% less nicotine,” which will further solidify the company's leadership in tobacco harm reduction.
- Significant Market Impact: A 2024 marketplace study showed that smokers using VLN® tobacco reduced their daily consumption by 40% over 12 weeks, indicating the product's effectiveness in reducing smoking and increasing quit attempts, potentially leading to improved public health outcomes.
- Brand Expansion Strategy: An increasing number of cigarette brands are launching VLN® products, offering alternatives with 95% less nicotine, which helps smokers reduce their nicotine intake while maintaining their habits, thereby enhancing market competitiveness.
- Proactive Regulatory Support: The company anticipates full FDA support for its renewal application, especially as VLN® products meet the FDA's proposed low nicotine guidelines, further reinforcing its market position.
See More
88th Emerging Growth Conference Scheduled for December 10-11, 2025
- Conference Schedule: The 88th Emerging Growth Conference is set for December 10-11, 2025, featuring a diverse range of growth companies showcasing their innovative products and services, aimed at attracting investor interest.
- Presenting Companies: Keynote speakers from firms such as OSR Holdings (NASDAQ: OSRH) and SBC Medical Group (NASDAQ: SBC) will present, likely increasing investor engagement and interest in these companies.
- Interactive Opportunities: Attendees can submit questions to presenting companies, fostering communication between investors and firms, which enhances the effectiveness of investment decisions.
- Media Impact: The conference serves as a platform for companies to showcase their offerings, effectively attracting potential investors and enhancing market visibility, which could lead to potential stock price increases.
See More
